티보자닙(Tivozanib)은 주로 신세포암 치료에 사용되는 티로신 키나아제 억제제(Tyrosine Kinase Inhibitors, TKIs)로 혈관 내피 성장인자 수용체(Vascular Endothelial Growth Factor Receptors, VEGFRs) 를 표적으로 하여 종양으로 가는 혈액 공급을 억제함으로써 암세포의 성장과 전이를 억제하는 것으로 알려져 있다. 신장에 발생하는 종양과 티보자닙의 연관성에 관한 논문은 비교적 많은 보고가 된 바 있으나 구강암에서의 티보자닙의 항암활성 효과는 아직 밝혀진 바가 거의 없다. 따라서 본 연구에서는 구강편평상피세포암종 세포주인 Ca9-22와 CAL-27세포에 티보자닙을 처리하여 암 발생 과정과 밀접한 관련이 있는 세포자멸사와 자가포식작용 사이의 연관성을 밝힘으로써 구강암의 치료제로서의 효능을 입증하기 위하여 시행되었다. 실험 결과 티보자닙은 Ca9-22와 CAL-27 세포에서 내인성 경로를 통한 세포자멸사와 초기 자가포식 작용 연관 단백질의 발현을 유의미하게 조절함으로써 효과적으로 항암 활성 효과를 나타내었음을 입증하였다.
Tivozanib is a tyrosine kinase inhibitor (TKI) used in the treatment of renal cell carcinoma. It targets vascular endothelial growth factor receptors (VEGFRs) within the tumor, inhibiting the blood supply to the tumor, which in turn, suppresses the growth and spread of cancer cells. While there have been numerous reports highlighting the association between diseases in the kidneys and Tivozanib, its pharmacological effects on oral cancer remain largely unexplored. Therefore, this study aimed to investigate the relationship between Tivozanib and the mechanisms related to cancer cell death (apoptosis) and autophagy in Ca9-22 and CAL-27 oral squamous cell carcinoma cell lines. The objective was to demonstrate an increased efficacy in treating oral cancer cells. The results showed that Tivozanib effectively exhibited its anti-cancer activity by regulating the expression of proteins associated with intrinsic cell apoptotic pathways and early autophagy in Ca9-22 and CAL-27 cells.
Tivozanib is a tyrosine kinase inhibitor (TKI) used in the treatment of renal cell carcinoma. It targets vascular endothelial growth factor receptors (VEGFRs) within the tumor, inhibiting the blood supply to the tumor, which in turn, suppresses the growth and spread of cancer cells. While there have been numerous reports highlighting the association between diseases in the kidneys and Tivozanib, its pharmacological effects on oral cancer remain largely unexplored. Therefore, this study aimed to investigate the relationship between Tivozanib and the mechanisms related to cancer cell death (apoptosis) and autophagy in Ca9-22 and CAL-27 oral squamous cell carcinoma cell lines. The objective was to demonstrate an increased efficacy in treating oral cancer cells. The results showed that Tivozanib effectively exhibited its anti-cancer activity by regulating the expression of proteins associated with intrinsic cell apoptotic pathways and early autophagy in Ca9-22 and CAL-27 cells.